ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

• ClinicalTrials.gov Identifier: NCT02384460
• Recruitment Status: Completed
• First Posted: March 10, 2015
• Results First Posted: October 16, 2018
• Last Update Posted: April 9, 2020
• Sponsor: Scioderm, Inc.
• Collaborator: Amicus Therapeutics
• Information provided by (Responsible Party): Scioderm, Inc.

Study Description

Brief Summary:

The aim was to assess the efficacy and safety of SD-101-6.0 cream versus Placebo (SD-101-0.0) cream in the treatment of skin lesions in participants with Epidermolysis Bullosa. Funding Source - United States Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD).

Condition or disease	Intervention/treatment	Phase
Epidermolysis Bullosa	Drug: SD-101-6.0 cream; Drug: Placebo (SD-101-0.0) cream	Phase 3

Detailed Description:

This was a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of SD-101-6.0 cream versus placebo (SD-101-0.0) cream on skin lesions in participants with Simplex, Recessive Dystrophic, or Junctional non-Herlitz Epidermolysis Bullosa. Epidermolysis Bullosa is a rare group of inherited disorders that typically manifest at birth as blistering and lesion formation on the skin in response to little or no apparent trauma. In this study, SD-101-6.0 cream or placebo (SD-101-0.0) cream was to be applied topically, once a day to the entire body for a period of 90 days. Participants had 1 target wound selected at baseline by the investigator. The selected target wound was required to have been present for at least 21 days. Photographic confirmation of the target wound location was collected at baseline, and the picture saved from the first visit was used to confirm location of the target wound at subsequent visits. The participant returned to the study site for Visit 2 (approximately 14 days from baseline), Visit 3 (approximately 30 days from baseline), Visit 4 (approximately 60 days from baseline), and Visit 5 (approximately 90 days from baseline) to have the target wound assessed for the level of healing. In addition, itching, pain, body surface area, target wound closure, and scarring of healed target wound were assessed at each visit. The ARANZ SilhouetteStar™ was used to measure the target wound at all visits.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 169 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
• Actual Study Start Date: March 11, 2015
• Actual Primary Completion Date: July 5, 2017
• Actual Study Completion Date: July 5, 2017

Arms and Interventions

Arm	Intervention/treatment
Experimental: SD-101-6.0 cream; SD-101-6.0 cream applied topically, once a day to the entire body for a period of 90 days	Drug: SD-101-6.0 cream; applied topically once a day for 90 days; Other Name: SD-101
Placebo Comparator: Placebo (SD-101-0.0) cream; SD-101-0.0 (placebo) cream applied topically, once a day to the entire body for a period of 90 days	Drug: Placebo (SD-101-0.0) cream; applied topically once a day for 90 days; Other Name: placebo

Outcome Measures

Primary Outcome Measures :

1. Time To Complete Target Wound Closure Within 3 Months [ Time Frame: From baseline to Month 3 visit ]
   Target wounds were monitored at each study visit for complete closure, defined as skin re-epithelialization without drainage. Time to target wound closure was measured from the date of the first administration of the study drug to the date of target wound closure. Participants were censored if they did not have a response within 3 months, or withdrew earlier before the confirmation of their target wound closing. This primary end point displays the mean time to complete target wound closure, analyzed using a Kaplan-Meier approach.
2. The Percentage Of Participants Experiencing Complete Closure Of Their Target Wound Within 3 Months [ Time Frame: From baseline to Month 3 visit ]
   Target wounds were monitored at each study visit for complete closure, defined as skin re-epithelialization without drainage. Participants were considered responders if they experienced complete wound closure at the Week 2 or Months 1, 2, or 3 visits. If a target wound was documented to have closed at a given visit, it was considered closed at all subsequent visits. This primary end point displays the percentage of participants from the ITT population who had complete target wound closure by the end of the study period (that is, 3 months). Analysis was performed on participants with post-baseline wound closure data.

Secondary Outcome Measures :

1. Percentage Of Participants Experiencing Complete Closure Of Their Target Wound At Month 1 And Month 2 Visits [ Time Frame: From baseline to Month 1 and Month 2 visits ]
   Target wounds were monitored at each study visit for complete closure, defined as skin re-epithelialization without drainage. The percentage of participants who completed target wound closure at the Month 1 and Month 2 study visits is displayed. If a target wound was documented to have closed at a given visit, it was considered closed at all subsequent visits.
2. Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin At Month 3 Visit [ Time Frame: Baseline, Month 3 visit ]
   Lesional skin was defined as areas that contained any of the following: blisters, erosions, ulcerations, scabbing, bullae, or eschars, as well as areas that were weeping, sloughing, oozing, crusted, or denuded. BSAI was calculated as a percentage, ranging from 0% to 100%, of affected body surface area, recorded for each defined body region (that is, head/neck, upper limbs, trunk [includes groin], and lower limbs), multiplied by the weighting factor, then summed for all body regions.
3. Change From Baseline In BSAI Of Total Body Wound Burden At Month 3 Visit [ Time Frame: Baseline, Month 3 visit ]
   Total body wound burden was calculated using BSAI. A wound defined as an open area on the skin (that is, epidermal covering disrupted). BSAI was calculated as a percentage, ranging from 0% to 100%, of affected body surface area, recorded for each defined body region (that is, head/neck, upper limbs, lower limbs, trunk [includes groin]), and multiplied by the weighting factor, then summed for all body regions.
4. Change From Baseline In Itching Score At Day 7 [ Time Frame: Baseline, Day 7 ]
   Itching was assessed using the 5-point Itch Man Pruritus Assessment Tool. For participants up to 5 years of age, itching was assessed using caretaker's response and participants 6 years of age and older self-reported their itching assessments based on the following scores: 0=Comfortable, no itch; 1=itches a little, does not interfere with activity; 2=itches more, sometimes interferes with activity; 3=itches a lot, difficult to be still, concentrate; 4=itches most terribly, impossible to sit still or concentrate. Itching scores were categorized into 3 groups based on improvement; Improved or No Itching, Not Improved, and Missing. An itching score reduction from baseline greater than or equal to 1 point on the scale was classed as improved.
5. Change From Baseline In Pain Score At Day 7 [ Time Frame: Baseline, Day 7 ]
   Change in pain assessed at Day 7 compared to baseline was measured using the Face, Legs, Activity, Cry, and Consolability (FLACC) behavioral scale for participants 1 month to 3 years of age. Each of the 5 FLACC categories was scored from 0 to 2, which resulted in a total score between 0 and 10 with 0=Relaxed and comfortable, 1 to 3=Mild discomfort, 4 to 6=Moderate pain, and 7 to 10=Severe discomfort/pain. For participants 4 years of age and older, the "Wong Faces Pain Scale" was used. This scale shows a series of faces ranging from a happy face at 0, which represents "no hurt," to a crying face at 10, which represents "hurts worst". Pain scores were categorized into 3 groups based on improvement: Improved or No Pain, Not Improved, and Missing. A pain score reduction from baseline greater than or equal to 2 points on the scale was classed as improved.

Eligibility Criteria

• Ages Eligible for Study: 1 Month and older (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Informed Consent form signed by the participant or participant's legal representative; if the participant was under the age of 18 but capable of providing assent, signed assent from the participant.
• Participant (or caretaker) must have been willing to comply with all protocol requirements.
• Diagnosis of Simplex, Recessive Dystrophic, or Junctional non-Herlitz EB.
• Participant must have had 1 target wound (size 10 to 50 cm^2) at study entry.
• Participants 1 month and older.
• Target wound must have been present for at least 21 days.

Exclusion Criteria:

• Participants who did not meet the entry criteria outlined above.
• Selected target wound did not have clinical evidence of local infection.
• Use of any investigational drug within the 30 days before enrollment.
• Use of immunotherapy or cytotoxic chemotherapy within the 60 days before enrollment.
• Use of systemic or topical steroidal therapy within the 30 days before enrollment. (Inhaled steroids and ophthalmic drops containing steroids were allowed).
• Use of systemic antibiotics within the 7 days before enrollment.
• Current or former malignancy.
• Arterial or venous disorder resulting in ulcerated lesions.
• Pregnancy or breastfeeding during the study. (A urine pregnancy test was performed at screening and every 30 days until the final visit for female participants of childbearing potential).
• Females of childbearing potential who were not abstinent and not practicing a medically acceptable method of contraception.

Contacts and Locations

Locations

United States, Arizona

Phoenix, Arizona, United States, 85016

United States, California

Redwood City, California, United States, 94063

United States, Colorado

Aurora, Colorado, United States, 80045

United States, District of Columbia

Washington, District of Columbia, United States, 20016

United States, Florida

Miami, Florida, United States, 33136

Miami, Florida, United States, 33155

United States, Illinois

Chicago, Illinois, United States, 60611

United States, Minnesota

Minneapolis, Minnesota, United States, 55455

United States, Missouri

Columbia, Missouri, United States, 65212

Saint Louis, Missouri, United States, 63110

United States, New Hampshire

Lebanon, New Hampshire, United States, 03756

United States, New Jersey

Hackensack, New Jersey, United States, 07601

United States, New York

East Setauket, New York, United States, 11733

New York, New York, United States, 10032

United States, North Carolina

Chapel Hill, North Carolina, United States, 27516

United States, Ohio

Cincinnati, Ohio, United States, 45229-3039

United States, Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

United States, South Carolina

Charleston, South Carolina, United States, 29425-5780

United States, Texas

Austin, Texas, United States, 78723

San Antonio, Texas, United States, 78218

United States, Washington

Seattle, Washington, United States, 98105

Australia, New South Wales

Kogarah, New South Wales, Australia, 2217

Australia, Victoria

Parkville, Victoria, Australia, 3050

Parkville, Victoria, Australia, 3052

Austria

Salzburg, Austria, 5020

France

Nice, France, 0-06200

Paris, France, 75015

Toulouse, France

Germany

Freiburg, Germany

Hannover, Germany

Israel

Tel Aviv, Israel

Italy

Milano, Italy, 20122

Lithuania

Kaunas, Lithuania

Netherlands

Groningen, Netherlands, 9713 GZ

Poland

Warszawa, Koszykowa, Poland

Serbia

Belgrade, Serbia

Spain

Madrid, Spain

United Kingdom

London, United Kingdom, WC1N 3JH

Sponsors and Collaborators

Scioderm, Inc.

Amicus Therapeutics

Investigators

• Study Director: Medical Monitor; Amicus Therapeutics

  Study Documents (Full-Text)

Documents provided by Scioderm, Inc.:

Study Protocol  [PDF] March 20, 2017

Statistical Analysis Plan  [PDF] March 22, 2018

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Murrell DF, Paller AS, Bodemer C, Browning J, Nikolic M, Barth JA, Lagast H, Krusinska E, Reha A; ESSENCE Study Group. Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE Study. Orphanet J Rare Dis. 2020 Jul 21;15(1):190. doi: 10.1186/s13023-020-01435-3.

Paller AS, Browning J, Nikolic M, Bodemer C, Murrell DF, Lenon W, Krusinska E, Reha A, Lagast H, Barth JA; ESSENCE Study Group. Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study). Orphanet J Rare Dis. 2020 Jun 23;15(1):158. doi: 10.1186/s13023-020-01419-3.

• Responsible Party: Scioderm, Inc.
• ClinicalTrials.gov Identifier: NCT02384460
• Other Study ID Numbers: SD-005; 2014-002288-14 ( EudraCT Number ); R01-005095-01 ( Other Identifier: Orphan Product Grant )
• First Posted: March 10, 2015
• Results First Posted: October 16, 2018
• Last Update Posted: April 9, 2020
• Last Verified: April 2020

Keywords provided by Scioderm, Inc.:

Amicus Therapeutics; Scioderm, Inc.; Simplex; Recessive Dystrophic; Junctional non-Herlitz; Epidermolysis Bullosa; SD-101 6%; SD-101-6.0; Allantoin 6%; Zorblisa

Additional relevant MeSH terms:

Epidermolysis Bullosa; Skin Abnormalities; Congenital Abnormalities; Skin Diseases, Genetic; Genetic Diseases, Inborn; Skin Diseases; Skin Diseases, Vesiculobullous